Boehringer Ingelheim wins China's first biopharmaceutical CMO pilot project
Boehringer Ingelheim China’s first client under the pilot is Beijing-based biotech company BeiGene
After China’s National People's Congress in late 2015 legalised biopharma contract manufacturing in mainland China, German pharmaceutical giant Boehringer Ingelheim has confirmed that its subsidiary, Boehringer Ingelheim China, is working on China’s first biopharma CMO pilot project.
'Under the [new] marketing authorisation holder system, drug holders are allowed to manufacture the drugs on their own or choose contract manufacturers instead. Contract manufacturing will therefore help separate drug marketing authorisation holders from drug production enterprises and significantly contribute to the industry’s growth [in China],' explained Steven Zhang, spokesman for Boehringer Ingelheim China, in Shanghai.
He added that the innovative CMO model will help provide Chinese patients with more high-quality innovative bio-medicines.
Boehringer Ingelheim China’s first client under the pilot is Beijing-based biotech company BeiGene. The new site, scheduled to start operation in the first quarter of next year, will provide biopharma CMO manufacturing for BeiGene’s self-development immuno-cancer therapies.
